Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Inquirer on MSN2d
Controlled drug Ketamine a lifeline for patients with severe depression in SingaporeSINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best known as a horse tranquilliser or party supplement, has ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback